



New Licensing Opportunity

Method for using Tethered BIS(Polyhydroxyphenyls) & O-Alkyl derivatives thereof in treating inflammatory conditions of central nervous system (CNS)

Title of Invention: Method for using Tethered BIS(Polyhydroxyphenyls) & O-Alkyl derivatives thereof in treating inflammatory conditions of central nervous system (CNS)

Category: Therapeutic

Field: Neuro-degenerative diseases (*Parkinson's, Huntington's, Alzheimer's, ALS, MS, Stroke, Dementia* etc.), *cancer*, and several inflammatory diseases (like *Arthritis*)

Inventor: Dr. Kenneth Hensley

Patent Application: US Patent Application # 20040014721. PCT Application # WO03/103583.

Background: Microglia are specialized myeloid (macrophage-like) cells in the CNS. Chronic microglial activation is harmful as it causes overproduction of neurotoxins like reactive oxygen species, and aids the propagation of inflammatory cytokine cascades. Microglial activation is a common pathological feature of neurological diseases. Dr. Hensley of OMRF has identified that inhibition of microglial activation could alleviate symptoms of many CNS diseases, cancers, and other inflammatory diseases involving pro-inflammatory cytokine action on microglial or macrophage-like cells.

Invention: Unique approach to inhibit chronic microglial activation using a class of compounds called "tethered" bis(polyhydroxyphenyls), which are also called "tethered" Dicatechols, and their O-Alkyl derivatives.

Disadvantages of

Traditional Approach:

No effective treatments available for most CNS diseases that this technology addresses. Prior to Dr. Hensley's invention of this technology, very little research was done by others on the effect of Dicatechols on inflammatory diseases or microglial biology. Attention of such prior research was limited to models of peripheral inflammation using "linked" (not tethered) Dicatechols.

Advantages of OMRF Technology: Tethered Dicatechols seem to be very effective in treating the disease states addressed by this technology. These are naturally occurring compounds and are small molecules that have the ability to penetrate through blood brain barrier. Technology has a strong IP position, which extends to the use of pro-drugs and derivatives of the compounds.

Stage of Development of Technology: Technology has undergone proof of concept studies and is ready for aggressive development. We are seeking licensing/research partners to bring this to market.



Dr. Kenneth Hensley



Oklahoma Medical Research Foundation

Contact: Manu S. Nair
Licensing Associate
755 Research Parkway, Suite 410
Oklahoma City, OK 73104-3600
405-271-1846
nairm@omrf.ouhsc.edu

A Cure
Is Out There